Dilated Cardiomyopathy Pipeline Insight

"DelveInsight’s, “Dilated Cardiomyopathy - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dilated Cardiomyopathy  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Dilated Cardiomyopathy: Understanding

Dilated Cardiomyopathy: Overview

Dilated Cardiomyopathy (DCM) is a condition characterized by an enlarged and weakened heart muscle, primarily affecting the ventricles. This enlargement impairs the heart's ability to pump blood effectively, leading to decreased cardiac output and, ultimately, heart failure. DCM can occur at any age but is most commonly diagnosed in middle-aged adults. It can be idiopathic (unknown cause) or secondary to various factors, including genetic mutations, infections, toxins, and systemic diseases.The symptoms of DCM can vary widely and may develop gradually or appear suddenly. Common symptoms include fatigue, shortness of breath (dyspnea), especially with exertion or when lying down (orthopnea), and swelling in the legs, ankles, and feet (peripheral edema). Patients may also experience palpitations, dizziness, and fainting episodes (syncope). As the condition progresses, signs of congestive heart failure, such as fluid retention, weight gain, and decreased exercise tolerance, become more prominent. 

The causes of DCM are multifactorial. Genetic predisposition plays a significant role, with mutations in genes encoding proteins of the cardiac muscle and cytoskeleton being identified in many cases. Other causes include viral infections (e.g., myocarditis), chronic alcohol abuse, and exposure to certain chemotherapy drugs. Autoimmune diseases and metabolic disorders like diabetes and thyroid disease can also contribute to the development of DCM. In many instances, however, the precise cause remains unknown. In DCM, the ventricular walls become thin and the chambers enlarge, leading to impaired systolic function. This dilation results in decreased ejection fraction and increased end-diastolic volume. Over time, the heart muscle may undergo fibrotic changes, further compromising its contractile function. Neurohormonal activation, including the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, occurs in response to reduced cardiac output, leading to fluid retention and increased vascular resistance, which exacerbates heart failure symptoms. 

Diagnosis of DCM typically involves a combination of clinical evaluation, imaging studies, and laboratory tests. Echocardiography is the primary imaging modality used to assess ventricular size, function, and ejection fraction. Cardiac MRI and genetic testing may be utilized for further evaluation. Blood tests, including biomarkers like B-type natriuretic peptide (BNP), can help assess the severity of heart failure. Treatment aims to manage symptoms, improve quality of life, and prevent disease progression. Medications such as ACE inhibitors, beta-blockers, and diuretics are commonly prescribed to reduce heart workload and control fluid retention. In advanced cases, device therapy (e.g., implantable cardioverter-defibrillators, cardiac resynchronization therapy) and surgical options like heart transplantation may be considered. Lifestyle modifications, including dietary changes, exercise, and avoidance of alcohol, are also essential components of managing DCM.

"Dilated Cardiomyopathy - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dilated Cardiomyopathy pipeline landscape is provided which includes the disease overview and Dilated Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Dilated Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dilated Cardiomyopathy  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Explore detailed insights into market forecast, emerging therapies, market trends, and key players shaping the Dilated Cardiomyopathy landscape - Dilated Cardiomyopathy Market

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dilated Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Dilated Cardiomyopathy.

Dilated Cardiomyopathy Emerging Drugs Chapters

This segment of the Dilated Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dilated Cardiomyopathy Emerging Drugs

 

• BC 007: Berlin Cures

BC 007 (Rovunaptabin), is a novel therapeutic candidate for the treatment of Dilated Cardiomyopathy. Through extensive research, Berlin Cures has developed a DNA-based aptamer BC 007 that specifically binds to and neutralizes functional autoantibodies against G protein-coupled receptors. In a controlled open-label Phase IIa study in subjects with heart failure, BC 007 achieved long-term neutralisation of functional autoantibodies after a single dose. By contrast, all subjects in the non-treated control group remained positive for functional autoantibodies throughout the duration of the study. Based on these encouraging data and the high unmet medical need, Berlin Cures will advance the clinical development of BC 007 through a controlled Phase IIb study in heart failure subjects.  Currently, the drug is in Phase II stage of its development for the treatment of Dilated Cardiomyopathy.

 

• AZD0233: AstraZeneca 

 AZD8233 is a novel investigational drug candidate being developed by AstraZeneca. The drug candidate is been administered via oral route. Currently, the drug is in Phase I stage of its development for the treatment of Dilated Cardiomyopathy.

 

Further product details are provided in the report……..

Dilated Cardiomyopathy: Therapeutic Assessment

• This segment of the report provides insights about the different Dilated Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
• Major  Players in Dilated Cardiomyopathy 
• There are approx. 8+ key companies which are developing the therapies for Dilated Cardiomyopathy. The companies which have their Dilated Cardiomyopathy drug candidates in the most advanced stage, i.e. phase II include, Berlin Cures.
• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dilated Cardiomyopathy: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dilated Cardiomyopathy therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dilated Cardiomyopathy drugs.

 

Dilated Cardiomyopathy Report Insights

• Dilated Cardiomyopathy  Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Dilated Cardiomyopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dilated Cardiomyopathy drugs?
• How many Dilated Cardiomyopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dilated Cardiomyopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dilated Cardiomyopathy therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Dilated Cardiomyopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Key Players

• Berlin Cures
• AstraZeneca
• Biohaven Pharmaceuticals
• Tenaya Therapeutics

 

Key Products

• BC 007
• AZD0233
• BHV-1600
• DWORF Gene Therapy Program For Dilated Cardiomyopathy (DCM)